New spinout AlveoGene, focused on transforming rare respiratory disease outcomes using inhaled gene therapy, has launched out of the Universities of Oxford and Edinburgh and Imperial College London.
Clinical trials have begun for a drug candidate for hard-to-treat cancers, discovered at the University of Edinburgh and licensed by US biopharmaceutical company Nuvectis Pharma, Inc.
A research team developing enzyme replacement therapies for people with rare diseases has been awarded £74,600 in funding from Scotland’s national economic development agency, Scottish Enterprise.
Here in Scotland, we currently have a confluence of factors – data capacity, clinical and academic expertise, and technology – that put us in pole position to translate our excellent liver disease research and to develop the innovative new treatments we need, writes Dr Prakash Ramachandran, MRC Senior Clinical Fellow and Consultant Hepatologist at the University of Edinburgh...
The Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of cell and gene therapies, has opened a facility in the Edinburgh BioQuarter, its first site in Scotland.
US biotech company Neurogene has announced that a new 'product candidate' for the treatment of Rett syndrome has been added to its development pipeline.
Invizius, the biotechnology spinout company developing treatments to suppress unwanted immune responses in dialysis, has been awarded a second Biomedical Catalyst grant by Innovate UK to research a new field of application for its H-Guard® technology.
Resolution Therapeutics, a biopharmaceutical spinout company developing macrophage cell therapy to treat advanced liver disease, has completed a £10 million financing extension from Syncona and announced a new collaboration with biotech firm panCELLa.
What’s your next challenge? Spin in, spin out or start up?
